Cargando…
Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy
Many anti-cancer drugs are difficult to formulate into an oral dosage form because they are both poorly water-soluble and show poor permeability, the latter often as a result of being an intestinal efflux pump substrate. To obtain a more water-soluble formulation, one can take advantage of the highe...
Autores principales: | Bohr, Adam, Nascimento, Thais Leite, Harmankaya, Necati, Weisser, Johan Juhl, Wang, Yingya, Grohganz, Holger, Rades, Thomas, Löbmann, Korbinian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369428/ https://www.ncbi.nlm.nih.gov/pubmed/30642009 http://dx.doi.org/10.3390/molecules24020266 |
Ejemplares similares
-
Improving Co-Amorphous Drug Formulations by the Addition of the Highly Water Soluble Amino Acid, Proline
por: Jensen, Katrine Tarp, et al.
Publicado: (2014) -
Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying
por: Craye, Goedele, et al.
Publicado: (2015) -
Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations
por: Mishra, Jaya, et al.
Publicado: (2018) -
Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin
por: Beyer, Andreas, et al.
Publicado: (2015) -
Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies
por: Liu, Jingwen, et al.
Publicado: (2021)